| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/14/2004 | EP1435925A2 Gap junctions and edhf |
| 07/14/2004 | EP1435924A2 Therapeutic composition and use |
| 07/14/2004 | EP1435918A1 Highly compressible ethylcellulose for tableting |
| 07/14/2004 | EP1435907A2 Compositions and methods for delivering antibacterial, antifungal and antiviral ointments to the oral, nasal or vaginal cavity |
| 07/14/2004 | EP1435899A1 A composition for promoting hair growth |
| 07/14/2004 | EP1372689B1 Use of ikk-beta inhibitors and method for discovery of said inhibitors |
| 07/14/2004 | EP1315793A4 Methods for culturing human lung mast cells and uses thereof |
| 07/14/2004 | EP1248802B1 Soluble ctla4 mutant molecules and uses thereof |
| 07/14/2004 | EP1248630B1 Use of a dermatological composition containing oligosaccharides for the treatment of skin diseases |
| 07/14/2004 | EP1228067B1 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| 07/14/2004 | EP1173186A4 Use of tagatose to enhance key blood factors |
| 07/14/2004 | EP1169026B1 Use of ap-1 activators to treat glaucoma and ocular hypertension |
| 07/14/2004 | EP1117736B1 Modified starch film compositions |
| 07/14/2004 | EP1083924B1 Glucagon-like peptide-1 (glp-1) improves beta-cell response to glucose in subjects with impaired glucose tolerance |
| 07/14/2004 | EP1017823B1 Engineered protein kinases which can utilize modified nucleotide triphosphate substrates |
| 07/14/2004 | EP1014986B1 A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT 1 BETA ANTAGONIST OR PARTIAL AGONIST |
| 07/14/2004 | EP1009427A4 USE OF FACTOR XIIIa INHIBITORS TO TREAT ATHEROSCLEROSIS |
| 07/14/2004 | EP0961775B1 Purine l-nucleosides, analogs and uses thereof |
| 07/14/2004 | EP0730601B1 Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections |
| 07/14/2004 | EP0723443B1 Use of alpha receptor antagonists for the treatment of chronic muscle pain |
| 07/14/2004 | CN1512886A Use of antiprogestins for prophylaxis and treatment or hormone-dependent diseases |
| 07/14/2004 | CN1512885A Pharmaceutical combinations |
| 07/14/2004 | CN1512882A Reconstitutable parenteral composition containing COX-2 inhibitor |
| 07/14/2004 | CN1512876A Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation |
| 07/14/2004 | CN1512868A Methods of preventing UVB-induced skin damage |
| 07/14/2004 | CN1511588A Japanese blood fluke nucleic acid vaccine |
| 07/14/2004 | CN1511542A Composition for improving obstacle under pharynx |
| 07/14/2004 | CN1511519A Therapy for immunological disease of type 2 T auxiliary cell mediated |
| 07/14/2004 | CN1157404C Novel fusidic acid derivatives |
| 07/14/2004 | CN1157380C Substituted polycyclic aryl and heteroaryl pyrymidinones useful as anticoagulants agents |
| 07/14/2004 | CN1157225C Lectin compositions and uses tehreof |
| 07/14/2004 | CN1157188C Method for inhibiting stress-activated protein kinases |
| 07/14/2004 | CN1157186C Cholinergic agents in the treatment of presbyopia |
| 07/14/2004 | CN1157185C Protein stabilized pharmacologically active agents, methods for preparation thereof and methods for use thereof |
| 07/14/2004 | CN1157181C Use of conjugated linoleic acid (CLA) for topical treatment of cellulite |
| 07/13/2004 | US6762341 Treating asthma in animals; antiinflammatory/bronchodilator agents; drug screening |
| 07/13/2004 | US6762318 Glucagon antagonists |
| 07/13/2004 | US6762283 Caspase-8 interacting proteins |
| 07/13/2004 | US6762195 Treating diseases mediated by tumor necrosis factor; inhibit angiogenesis and treatment of cancer, inflammatory, and autoimmune diseases |
| 07/13/2004 | US6762176 Inhibiting no-synthase enzymes producing nitrogen monoxide and/or trapping reactive forms of oxygen; inhibit lipidic peroxidation |
| 07/13/2004 | US6762174 Beta-alethine with melphalan or cyclophosphamide; prevents clinical appearance of a neoplastic or pre-neoplastic condition; immunomodulation; enhancing cell growth, vitality, differentiation; antisenescence |
| 07/13/2004 | US6762051 Methods of inhibiting helicobacter pylori |
| 07/13/2004 | US6762021 Method for diagnosis of crohn's disease |
| 07/13/2004 | US6761914 And an antigen that is preferably a recombinant fusion protein; from seeds from oilseed crops, such as soybean, rapeseed, sunflower and palm |
| 07/13/2004 | US6761901 Proliposomal compositions that are advantageously used to deliver biologically active compounds to the gastrointestinal tract after oral administration. |
| 07/13/2004 | CA2453282A1 Method of modulating the basal metabolic rate of a dieting mammal by administration of a metabolic modulating agent to the dieting mammal |
| 07/13/2004 | CA2311356C Method for treating alzheimer's disease |
| 07/13/2004 | CA2288913C Membrane system for controlled tissue regeneration in cases of diseases of the peridontium |
| 07/13/2004 | CA2260143C Anthelmintic formulations |
| 07/13/2004 | CA2155020C Antiviral naphthoquinone compounds, compositions and uses thereof |
| 07/13/2004 | CA2131528C Methods and compositions for targeting the vasculature of solid tumors |
| 07/13/2004 | CA2067062C Infusion preparation |
| 07/08/2004 | WO2004057031A2 Methods for identifying therapeutic agents of atherosclerotic plaque lesions |
| 07/08/2004 | WO2004056971A2 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
| 07/08/2004 | WO2004056762A2 Novel aminobenzophenone compounds |
| 07/08/2004 | WO2004056750A1 Cyclopentil-substituted glutaramide compounds as endopeptidase inhibitors |
| 07/08/2004 | WO2004056396A1 DOSAGE FORMS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS WITH IMPROVED PERFORMANCE |
| 07/08/2004 | WO2004056395A1 Compositions of cholesteryl ester transfer protein inhibitors and hmg-coa reductase inhibitors |
| 07/08/2004 | WO2004056394A1 Combinations of a vanilloid antagonist and an nsaid for the treatment of pain |
| 07/08/2004 | WO2004056393A1 Agent with a retarded release of substances |
| 07/08/2004 | WO2004056376A1 Pharmaceutical formulations containing nitrate |
| 07/08/2004 | WO2004056375A1 Agent for decreasing appetite and for producing a satiation effect, for reducing weight and for lowering the cholesterol level |
| 07/08/2004 | WO2004056372A1 Use of aglycon protopanaxadiol in cancer therapy |
| 07/08/2004 | WO2004056371A1 Use of aglycon protopanaxatriol in cancer therapy |
| 07/08/2004 | WO2004056370A1 Use of a fatty acid composition for treatment of male infertility |
| 07/08/2004 | WO2004056360A1 Methods and dosage forms for reducing heart attacks in a hypertensive individual with a diuretic or a diuretic and an ace inhibitor combination |
| 07/08/2004 | WO2004056359A1 Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
| 07/08/2004 | WO2004056356A1 Oil-acid emulsion and use thereof |
| 07/08/2004 | WO2004056353A2 Device and method for delivering mmp inhibitors |
| 07/08/2004 | WO2004056349A2 Methods and compositions for the treatment of herpes virus infections using cyclooxygenase-2 selective inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents |
| 07/08/2004 | WO2004056342A1 Process for preparing combination pharmaceutical formulations using supercritical fluids |
| 07/08/2004 | WO2004056341A1 Process for preparing pharmaceutical formulations using supercritical fluids |
| 07/08/2004 | WO2004056320A2 Compositions of non-steroidal anti-inflammatory drugs decongestants and anti-histamines |
| 07/08/2004 | WO2004056311A2 Stimuli-responsive systems for controlled drug delivery |
| 07/08/2004 | WO2004056305A2 Administration of capsaicinoids |
| 07/08/2004 | WO2004056208A1 Stimulation of in vivo production of proteins with formulation comprising leucine |
| 07/08/2004 | WO2004056181A1 Organ preconditioning, arrest, protection, preservation and recovery (2) |
| 07/08/2004 | WO2004056180A1 Organ preconditioning, arrest, protection, preservation and recovery (1) |
| 07/08/2004 | WO2004043393A3 Compositions for diabetes treatment and prophylaxis |
| 07/08/2004 | WO2004037184A3 Methods for the treatment of skin disorders |
| 07/08/2004 | WO2004034990A3 Methods and compositions for use in treating cancer |
| 07/08/2004 | WO2004032876A9 Deguelin as a chemopreventive agent for lung cancer |
| 07/08/2004 | WO2004028634A9 Method and composition for treating alzheimer's disease and dementias of vascular origin |
| 07/08/2004 | WO2004026234A3 Method of treating leukemia with a combination of suberoylanilide hydromaxic acid and imatinib mesylate |
| 07/08/2004 | WO2004018010A3 Methods of drug delivery using sulphated chitinous polymers |
| 07/08/2004 | WO2004017896A3 Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist |
| 07/08/2004 | WO2004014322A3 Immunomodulatory compositions, methods of making, and methods of use thereof |
| 07/08/2004 | WO2004014301A3 PSMCs AS MODIFIERS OF THE RB PATHWAY AND METHODS OF USE |
| 07/08/2004 | WO2004012653A3 Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compostions thereof |
| 07/08/2004 | WO2004009072B1 Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies |
| 07/08/2004 | WO2004009017A3 Modulators of the glucocorticoid receptor and method |
| 07/08/2004 | WO2004006853A3 Treatment and prophylaxis with 4-1bb-binding agents |
| 07/08/2004 | WO2004004641A3 PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPα SECRETION AND IMPROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS |
| 07/08/2004 | WO2003103663A3 Substituted pyrrolines as kinase inhibitors |
| 07/08/2004 | WO2003093322A9 Carrageenan based antimicrobial compositions |
| 07/08/2004 | WO2003092625A3 Carvedilol formulations |
| 07/08/2004 | WO2003090676A3 Immunogenic agent therapy using plasmapheresis or exchange transfusion |
| 07/08/2004 | WO2003072061A3 Methods and compositions for treating gastrointestinal toxicity induced by cytoablative therapy |
| 07/08/2004 | WO2003070192A3 Compositions and methods for surrogate antibody modulation of an immune response and transport |
| 07/08/2004 | WO2003066822A3 Truncated aggrecanase molecules |